NEW YORK, August 10, 2025 — Leads & Copy — IO Biotech (Nasdaq: IOBT) will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 AM ET to disclose the topline results of the pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) of Cylembio, its investigational cancer vaccine, in combination with pembrolizumab vs. pembrolizumab alone as a first-line treatment for advanced melanoma.
The IO Biotech management team will host a webcast/conference call to discuss the topline results from the Phase 3 trial of Cylembio. Those who would like to participate may access the live webcast or register in advance for the teleconference. A replay of the webcast will be available on the IO Biotech website following the live event.
IO Biotech is developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. IO Biotech is advancing its lead cancer vaccine candidate, Cylembio®, in clinical trials and has been granted a Breakthrough Therapy Designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
Contacts:
Investors: Maryann Cimino, Director of Investor Relations, IO Biotech, Inc., 617-710-7305, mci@iobiotech.com
Media: Julie Funesti, Edelman, 917-498-1967, julie.funesti@edelman.com
Source: IO Biotech
